DIA 48th Annual Meeting
Click here to go to the previous page
Defining Study Endpoints in 2012: The Journey Continues
Track : Track 07: Processes and Technologies for Clinical Research
Program Code: 206
Date: Tuesday, June 26, 2012
Time: 8:00 AM to 9:30 AM  EST
CHAIR :
 John Weiler, CompleWare Corporation, United States
PRESENTER (S):
 Laurie Burke, FDA, United States
 John Powers, SAIC/National Institutes of Health, United States
Description
This session will bring together life sciences professionals including regulatory authorities to discuss the taxonomy used for study endpoints and the importance of identifying what is meaningful to be measured before focusing on how to measure it.

Learning Objectives:
Differentiate a patient reported outcome from an observer reported outcome
Define a sign as contrasted with a symptom in the context study endpoints
Discuss reasons why the concept behind a study endpoint should be defined prior to selecting the study endpoint itself.